Maharashtra Seamless Limited has disclosed a substantial acquisition of shares by Haryana Capfin Limited under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The disclosure was filed on February 25, 2026, and communicated to both BSE Limited and National Stock Exchange of India Limited.

Acquisition Details

Haryana Capfin Limited, identified as belonging to the promoter group, acquired additional shares in Maharashtra Seamless Limited through open market transactions. The acquisition period spanned from March 11, 2025, to February 23, 2026.

Share Holding Changes

The transaction involved the acquisition of 603,260 shares, representing 0.46% of the total share capital. This acquisition resulted in a change in Haryana Capfin Limited's shareholding pattern in Maharashtra Seamless Limited.

Company Capital Structure

Maharashtra Seamless Limited's equity share capital remained constant throughout the acquisition period. The company's shares are listed on both major Indian stock exchanges.

Regulatory Compliance

The disclosure was signed by Sandhya Tiwari, Company Secretary of Haryana Capfin Limited, and filed from Gurugram on February 25, 2026. Maharashtra Seamless Limited's Company Secretary, Ram Ji Nigam, communicated this disclosure to the stock exchanges, ensuring compliance with SEBI regulations regarding substantial acquisitions of shares and takeovers.

Pfizer Limited has delivered impressive financial results for the quarter ended December 31, 2025, demonstrating strong growth across key performance metrics. The pharmaceutical giant's quarterly performance reflects robust operational execution and market positioning in the competitive healthcare sector.

Financial Performance Overview

The company's financial results for Q3FY26 showcase significant improvement across multiple parameters. Total income reached ₹683.24 crore, marking a substantial 17.65% increase from ₹580.75 crore reported in the corresponding quarter of the previous fiscal year.

Profitability Analysis

Pfizer Limited demonstrated strong profitability metrics during the quarter. Net profit before tax increased to ₹191.95 crore from ₹172.44 crore in the same period last year, representing an 11.32% growth. The company's net profit after tax stood at ₹141.84 crore, compared to ₹127.60 crore in Q3FY24, showing an 11.18% improvement.

The company's total comprehensive income for the quarter reached ₹143.71 crore, slightly higher than the net profit after tax, indicating positive other comprehensive income components. This comprehensive performance reflects the company's ability to generate value beyond core operational activities.

Nine-Month Performance

For the nine-month period ended December 31, 2025, Pfizer Limited maintained strong momentum with total income of ₹2,037.65 crore. The company achieved net profit after tax of ₹522.61 crore for the nine-month period, with earnings per share reaching ₹114.24.

Capital Structure

The company maintained a stable capital structure with equity share capital of ₹45.75 crore, consisting of shares with a face value of ₹10 each. The consistent capital base provided a solid foundation for the company's growth initiatives and operational expansion.

Regulatory Compliance

The financial results were announced in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The detailed quarterly financial results are available on stock exchange websites and the company's official website, ensuring transparency and accessibility for stakeholders and investors.